Loading clinical trials...
Loading clinical trials...
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Janssen Research & Development, LLC
NCT07478458 · ADHD - Attention Deficit Disorder With Hyperactivity
NCT06655610 · ADHD - Attention Deficit Disorder With Hyperactivity
NCT07217652 · Schizophrenia, Attention Deficit Disorder With Hyperactivity (ADHD)
NCT06860763 · Acupuncture, ADHD - Attention Deficit Disorder With Hyperactivity, and more
NCT06685601 · ADHD - Attention Deficit Disorder With Hyperactivity
Janssen Investigative Site
Titusville, New Jersey
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions